Bayer AG, Wuppertal, Germany, indicated that it may be considering a merger with another major pharmaceutical company.
Bayer AG, Wuppertal, Germany, indicated that it may be considering a merger with another major pharmaceutical company.
In an interview with the Wall Street Journal in June, Horst Meyer, the general manager of Bayer's pharmaceuticals business group, said the company wants to boost its global market share from its current state of 2.3% to more than 4%. The only way that the company can achieve this growth, Meyer told the Journal, is through "business combinations."
Despite achieving sales growth of 30% in the United States in 1997 - almost twice as much as the business group as a whole - Bayer did not move into the top 10 in industry ranking. It currently stands in twelfth place, behind Abbott Laboratories, according to Plymouth, PA-based IMS America.
In a recent press conference, Meyer indicated that marketing alliances are and will continue to be a standard way for Bayer to sell its products in North America.
The company's most significant alliances "involve the licensing of nisoldipine, a calcium antagonist, to Zeneca, and of miglitol, an antidiabetic drug, to Sanofi and Sanwa," Meyer said. Bayer also comarkets products with Smith-Kline Beecham and Fournier.
Meyer did not indicate whether one or several of these business partners was a possible candidate for a merger. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.